ClinicalTrials.gov
ClinicalTrials.gov Menu

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01392079
Recruitment Status : Unknown
Verified May 2015 by Stephan Stilgenbauer, University of Ulm.
Recruitment status was:  Active, not recruiting
First Posted : July 12, 2011
Last Update Posted : May 28, 2015
Sponsor:
Collaborators:
IMSE, TU Munich (Biometry)
WiSP Wissenschaftlicher Service Pharma GmbH
German CLL Study Group
Information provided by (Responsible Party):
Stephan Stilgenbauer, University of Ulm

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Actual Primary Completion Date : December 2014
  Estimated Study Completion Date : December 2016